WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
maximize
Machine translation
1. (WO2010028256) PREDICTIVE BIOMARKERS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

What is claimed:

1. A method for predicting a characteristic of a human subject; said method comprising assaying a DNA or RNA sample from the subject for the presence or absence of one or more single nucleotide polymorphisms selected from the group consisting of the SNPs located at the locus represented by position 61 of each of the sequences of SEQ ID NO: 6 (SVIL), SEQ ID NO: 20 (SLC22A3), SEQ ID NO: 3 (NRP2), SEQ ID NO: 2 (TTN), SEQ ID NO: 27 (H 19), SEQ ID NO: 12 (ID3), SEQ ID NO: 9 (MIPEP), SEQ ID NO: 21 (CPVL), SEQ ID NO: 23 (DEPDC6), SEQ ID NO: 26 (BTAFl), and SEQ ID NO: 29 (DIS3L); and correlating any such single nucleotide polymorphisms thus identified in the subject to the characteristic; wherein the characteristic is selected from the group consisting of: (a) the expected response of the subject's maximal oxygen uptake to an aerobic exercise program, (b) the expected response of the subject's aerobic capacity to an aerobic exercise program, and (c) the subject's risk of cardiovascular disease.

2. The method of Claim 1, wherein the characteristic is the expected response of the subject's maximal oxygen uptake to an aerobic exercise program.

3. The method of Claim 1, wherein the characteristic is the expected response of the subject's aerobic capacity to an aerobic exercise program.

4. The method of Claim 1, wherein the characteristic is the subject's risk of cardiovascular disease.

5. The method of Claim 1, wherein the method comprises assaying the DNA or RNA sample for the presence or absence of five or more single nucleotide polymorphisms as recited.

6. The method of Claim 1, wherein the method comprises assaying the DNA or RNA sample for the presence or absence of eleven or more single nucleotide polymorphisms as recited.

7. The method of Claim 1, wherein the method comprises assaying the DNA or RNA sample for the presence or absence of all of the single nucleotide polymorphisms as recited.

8. A method for predicting a characteristic of a human subject; said method comprising assaying an RNA sample from the subject for the level of transcription of one or more RNAs selected from the group consisting of SEQ ID NOs: 37 - 355; and correlating the level of transcription of the one or more RNAs to the characteristic; wherein the characteristic is selected from the group consisting of: (a) the expected response of the subject's maximal oxygen uptake to an aerobic exercise program, (b) the expected response of the subject's aerobic capacity to an aerobic exercise program, and (c) the subject's risk of cardiovascular disease.

9. The method of Claim 8, wherein the characteristic is the expected response of the subject's maximal oxygen uptake to an aerobic exercise program.

10. The method of Claim 8, wherein the characteristic is the expected response of the subject's aerobic capacity to an aerobic exercise program.

11. The method of Claim 8, wherein the characteristic is the subject's risk of cardiovascular disease.

12. The method of Claim 8, wherein the method comprises assaying the RNA sample for the presence or absence of fifty or more RNAs as recited.

13. The method of Claim 8, wherein the method comprises assaying the RNA sample for the presence or absence of 100 or more RNAs as recited.

14. The method of Claim 8, wherein the method comprises assaying the RNA sample for the presence or absence of all of the RNAs as recited.

15. A method for identifying one or more single nucleotide polymorphisms in a human subject as markers that are correlated to the expected level of response by the subject to an intervention; said method comprising the steps of: (a) selecting a group of human subjects; (b) collecting an RNA sample from each of the subjects; (c) assaying each of the RNA samples for the level of transcription of RNA for 10 or more different genes; (d) exposing each of the subjects to the intervention after collecting the RNA samples; (e) determining the response level of each subject to the intervention; (f) identifying individuals within the group having a high response to the intervention and individuals within the group having a low response to the intervention; (g) correlating the assayed RNA levels to high response, or to low response; (h) validating the hypothesized correlations by repeating steps (a) through (g) in at least one additional group of human subjects; and correlating genomic single nucleotide polymorphisms in the DNA coding sequences to the corresponding RNAs correlated to high response, or to low response, or both.

16. A kit comprising single-stranded nucleic acids that are complementary to or identical to at least 5 consecutive nucleotides around the single nucleotide polymorphisms of five or more sequences selected from the group consisting of the single nucleotide polymorphisms listed in Table 6 of the specification.

17. A kit comprising 100 or more of single-stranded nucleic acids that are complementary to or identical to at least 5 consecutive nucleotides around the sequences selected from the group consisting of the sequences listed in Table 4 of the specification.